BRIEF published on 05/22/2025 at 07:05, 1 year 2 months ago Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011 FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease
PRESS RELEASE published on 05/22/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
BRIEF published on 05/15/2025 at 07:05, 1 year 2 months ago Relief Therapeutics Announces 2025 AGM Agenda Annual General Meeting Financial Statements Shareholder Voting Board Re-election Compensation Approval
PRESS RELEASE published on 05/15/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Publishes 2025 Annual General Meeting Agenda Relief Therapeutics announces agenda for its 2025 Annual General Meeting featuring key resolutions and re-elections. Meeting scheduled for June 12 in Geneva, Switzerland Shareholders Switzerland Relief Therapeutics Agenda 2025 Annual General Meeting
BRIEF published on 04/10/2025 at 07:05, 1 year 3 months ago Relief Therapeutics Announces 2024 Financial Results and Strategic Progress Biopharmaceutical Relief Therapeutics Rare Diseases 2024 Financial Results Pipeline Progress
PRESS RELEASE published on 04/10/2025 at 07:00, 1 year 3 months ago Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports 2024 financial results and provides a corporate update, emphasizing operational achievements, pipeline momentum, and strengthened financial position Biopharmaceutical Corporate Update Relief Therapeutics Rare Diseases 2024 Financial Results
BRIEF published on 03/06/2025 at 07:05, 1 year 5 months ago Relief Therapeutics Ends Merger Discussions with Renexxion Shareholder Value Relief Therapeutics Strategic Objectives Renexxion Merger Termination
PRESS RELEASE published on 03/06/2025 at 07:00, 1 year 5 months ago Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion Relief Therapeutics terminates merger discussions with Renexxion after failing to meet key conditions. Company remains well-positioned with robust pipeline and cash reserves Relief Therapeutics Cash Reserves Therapeutic Pipeline Renexxion Merger Discussions
BRIEF published on 02/11/2025 at 07:05, 1 year 5 months ago European Patent Office Grants Relief Therapeutics Patent for RLF-TD011 Biopharmaceuticals Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa
PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 5 months ago Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Relief Therapeutics obtains European Patent Office grant for RLF-TD011, securing patent protection for epidermolysis bullosa treatment. Company advances wound care solution Relief Therapeutics European Patent Office Epidermolysis Bullosa Wound Treatment RLD-TD011
Published on 08/07/2026 at 00:45, 7 hours 13 minutes ago NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 8 hours 43 minutes ago LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 9 hours 43 minutes ago Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
Published on 08/06/2026 at 22:05, 9 hours 53 minutes ago Innodata Reports Record Second Quarter 2026 Results
Published on 08/06/2026 at 22:00, 9 hours 58 minutes ago Gold Terra Announces Closing of Second Tranche of the C$10.8M LIFE
Published on 08/07/2026 at 07:30, 28 minutes ago AUSTRIAN POST IN H1 2026: Revenue increase despite challenging market environment; Growth in e-commerce and declining mail business
Published on 08/07/2026 at 07:00, 58 minutes ago Cicor signed a CHF 425 million unsecured term and revolving credit facilities agreement to support its next phase of growth
Published on 08/07/2026 at 06:59, 59 minutes ago Allianz delivers record result and is well on track to achieve its targets
Published on 08/07/2026 at 06:30, 1 hour 28 minutes ago Avolta acquires majority stake in Penha Duty Free Group
Published on 08/07/2026 at 06:30, 1 hour 28 minutes ago Mobimo Holding AG: Mobimo with strong operational performance in the first half of 2026
Published on 08/06/2026 at 18:26, 13 hours 32 minutes ago Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 17:45, 14 hours 13 minutes ago Declaration of voting rights at the end of July 2026
Published on 08/06/2026 at 17:35, 14 hours 23 minutes ago Groupe des Assurances du Crédit Mutuel (GACM)’s Solvency II ratio was 227% as of June 30, 2026
Published on 08/06/2026 at 17:35, 14 hours 23 minutes ago Availability of the financial statements of Groupe des Assurances du Crédit Mutuel for the first half of 2026
